Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Los términos de búsqueda han de ser en inglés.

Nuevo método de transporte de células madre a temperatura ambiente para abrir nuevos mercados


Oferta Tecnológica
Una pyme británica de biotecnología ha desarrollado una tecnología de almacenamiento y transporte de células humanas viables a temperatura ambiente. Esta tecnología fácil de usar y respetuosa con las células evita los problemas de transporte criogénico y abre nuevos mercados para realizar ensayos basados en células en formatos listos para usar y para biologística. El método encapsula las células humanas en un gel de alginato que facilita su uso, adaptación, almacenamiento y transporte. Su excelente viabilidad se mantiene incluso a temperatura ambiente. La empresa busca proveedores de células primarias y células madre, organoides y microtejidos, productos de biologística y productos de terapia celular con el fin de establecer acuerdos de cooperación y comercialización con asistencia técnica.


Novel method to enable ambient temperature transport of stem cells, opening up new markets
A UK-based biotech SME has developed a technology for the storage and transport of viable human cells at near-room temperature. Cell-and user-friendly, this overcomes the problems of cryoshipping and opens up the markets for cell-based assays in a ready-to-use format, and biologistics. The company is looking for providers of primary and stem cells, organoids and micro-tissues, biologistics, and cell therapy products, for technical cooperation and commercial agreements with technical assistance.
The potential of cell-based therapies has been well established and there is a good number of companies and organisations providing primary cells and pluripotent stem cells.

The users of these cells are in hospitals around the country or in a different country. The logistics of these chains can be very complicated. Some cell types one must not freeze, for others, the protocols and requirements for transport are quite complex and expensive.

A UK university spinout has developed a method of encapsulating human cells in an alginate gel that makes them practical to use, adaptable and easy to store and transport. Excellent viability is maintained even at near-room temperature.

A range of modifications to the method have been tested for a variety of cell types. The cells consistently prove to preserve their quality for therapeutic or assay purposes. This overcomes the barriers presented by the current need for cryo-shipping.
This will help open up the market for the supply of cells, tissues and assays in a ready-to-use format, allowing suppliers to increase the range of assays available to consumers and to scale up their businesses.

Encapsulating cells in the alginate hydrogel is a simple process, capable of preserving the viability and functionality of cells at temperatures between 4 and 21°C for extended periods of time, up to 2 weeks. Cells are encapsulated by in situ formation of the gel for shipping in plates, beads or vials, and can be rapidly released from the gel by the addition of a simple buffer.

The UK company is seeking partnerships with companies network-wide who either:

· sell high value cell assays and cells for R-Y-D purposes (in drug discovery and testing, for example);
· Biologistics providers who need cGMP (Current Good Manufacturing Practice) compliant transport protocols;
· Developers of new cell therapy products.

The co-operation will start with a brief technical project to choose or optimise the exact protocols by fine tuning the hydrogel. The UK company will then remain to supply the reagents on a needs basis under a commercial agreement with technical assistance.
Advantages and Innovations:
The discovery of this application for alginate gives a number of direct and indirect advantages. In essence it allows new supply routes so that the whole industry of stem cells, primary cells, organoids and micro-tissues can grow much more rapidly.
Stage of Development:
Already on the market
Patent(s) applied for but not yet granted
CommeR Statunts Regarding IPR Status:
The first patent is granted in Europe and is pending elsewhere. A further patent application has been filed as a GB priority filing in January 2018 and will be filed worldwide at entry into national phase.

Partner sought

Type and Role of Partner Sought:
Type of partner sought: industry and public organisations
Specific activity of partner sought: provision of primary cells and stem cells for R-Y-D or therapeutic purposes, usage of the same in medicinal products, biologistics.
Role of partner sought: The cooperation will begin with a short (2-3 weeks) technical project to optimise the performance of the methods for the particular cell or tissue type desired by the partner, taking into account the nature of the biological and the format required for transport (plates, beads, discs, vials, syringes...). Once success has been demonstrated and the method reduced to a written protocol, the technology will be transferred to the partner´s laboratory for them to operate in their hands. The UK partner will then supply all the components on a commercial basis and remain available for any technical assistance needed.


Type and Size of Client:
Industry SME <= 10
Already Engaged in Trans-National Cooperation:
Languages Spoken:


Technology Keywords:
06001019 Tecnologías de células madre